Collaborate Disseminate
Some sharks get a new set of teeth every few weeks, while crocodiles can go through thousands of chompers in their long lifetimes. Yet the ability to endlessly replace our pearly whites is something that’s eluded us and nearly all other mammals. By the… Continue reading Humans may soon grow new teeth, with promising drug trial set
Injecting antibodies from a healthy person into someone suffering from rheumatoid arthritis can reduce inflammation and slow bone degeneration, but how this occurs has remained largely unknown until now. Researchers have uncovered the molecular pathway… Continue reading Molecular discovery may mean new treatments for rheumatoid arthritis
A Phase 3 clinical trial of the drug donanemab has shown it can significantly slow cognitive and functional decline in people with early-stage Alzheimer’s disease, compared with existing treatments.
Category: Health & Wellbeing, Lifestyle
Tags: Alzheimer’s Disease, Dementia, Immunotherapy, Drug, Neural Network, antibodies
Continue reading Trial drug shown to significantly slow early Alzheimer’s decline
Researchers have discovered new information about how the body’s immune system works, simultaneously calling into question decades of understanding about the process of antibody-mediated immunity and opening the door for advancements in immunological t… Continue reading New study challenges decades-long understanding of our immune system
In the quest to combat Alzheimer’s disease, researchers have been hopeful about the use of antibodies to destroy peptides in the brain that cause damaging tangles and plaque buildups. So far though, such treatments have been unsuccessful. Postulating that the issue had to do with the antibodies getting blocked by the blood-brain barrier, scientists have found a way to sneak them into the brains of mice afflicted with the disease, and have seen encouraging results.
Tags: Alzheimer’s Disease, Blood-brain barrier, antibodies, Brain, Neuroscience
Continue reading Sugar-coated antibodies cross blood-brain barrier to fight Alzheimer’s
Light-activated antibody therapy could pave the way for new acutely targeted treatment of cancer cells. Scientists at the University of East Anglia in the UK have successfully engineered antibody fragments that are activated by a specific UV light wave… Continue reading Light therapy could ease side effects for cancer sufferers
The U.S. Food and Drug Administration (FDA) has approved a new drug for patients in the early-stages of Alzheimer’s disease. Called Leqembi (lecanemab) the treatment was heralded last year as a major breakthrough in Alzheimer’s therapy following early Phase 3 data indicating it could slow the progression of cognitive decline. But growing concerns over the drug’s safety and real-world efficacy have led to acrimonious division amongst researchers, with some suggesting the drug should not be authorized for wide use.
Tags: Alzheimer’s Disease, FDA, Dementia, Drugs, antibodies
Continue reading Another controversial FDA approval for a new Alzheimer’s medication
New data from an ongoing Phase 1/2 clinical trial has revealed an experimental immunotherapy led to successful response rates in 73% of patients suffering from multiple myeloma, a deadly form of blood cancer. Based on this promising data, an applicatio… Continue reading New blood cancer therapy successful in three-quarters of trial patients
According to the latest modeling from the Centers for Disease Control and Prevention (CDC), a pair of Omicron subvariants (BQ.1 & BQ.1.1) now account for half of all SARS.CoV.2 infections in the United States, swiftly surpassing the previously dominant… Continue reading Omicron BQ variants dominant in US, last antibody therapies falter
In the first big real-world test for monoclonal antibodies against malaria a new study has reported extraordinarily promising results, with a novel therapy found to be 88.2% effective at preventing infections across a six-month period. The results add … Continue reading Antibody therapy proves 88% effective at preventing malaria infections